Ofer Gonen

ColBar LifeSciences Ltd. develops technology for tissue regeneration and tissue engineering. It manufactures and commercializes bio surgical products for applications in reconstructive medicine and tissue engineering. Its main focus is on the repair of damaged tissue in the human body like soft tissue, bone and skin. The company was founded in 1995 and is headquartered in Herzliya, Israel.

Part of Fortive Corp., Biomedical Instruments Division of Lionheart Tech, Inc. is a private company based in Carson City, NV. Biomedical Instruments Division of Lionheart Tech, Inc. develops, markets, and manufactures quality assurance instrumentation, software and systems, and clinical training tools for hospital bioengineering departments. The company was acquired by Fluke Corp. from Lionheart Technologies LLC on April 12, 2002 for $25 million.

Clal Biotechnology Industries Ltd. (Clal Biotechnology Industries) is a venture capital division of Clal Biotechnology Industries Ltd. founded in 1993. The firm is headquartered in Tel Aviv, Israel.

Andromeda Biotech Ltd. develops treatment for autoimmune diabetes. The company was founded in 2007 and is headquartered in Rehovot, Israel.

Braintact Ltd. engages in the development of neurodegenerative disorder drugs. The company was founded by Gadi Lipiner and is headquartered in Kiryat Shmona, Israel.

Thrombotech Ltd. is an Israel-based biotechnological company that is based on years of cutting-edge thrombotic research at the Hadassah Medical Center in Jerusalem. Thrombotech developed a peptide called THR-18, which allows the existing thrombolytic stroke medication to easily dissolve blood clots, extending its short therapeutic time window and diminishing life-threatening side effects. The company was founded in 2000 and is headquartered in Rehovot, Israel.

Part of Clal Biotechnology Industries Ltd., Clal Life Sciences (CLS) LP is a venture capital fund.

Avraham Pharmaceuticals Ltd. develops pharmaceutical products for prevention and treatment of neurodegenerative disorders. Its lead product candidate, Ladostigil is designed to provide treatment for Mild Cognitive Impairment. The firm’s product candidate is a multifunctional compound that combines neuroprotective mechanisms: reducing oxidative stress and microglial activation, and inhibiting proinflamtory cytokines. The company was founded in 2010 by David Warshawsky and is headquartered in Yavneh, Israel.

Biomedical Investments operates as a private investment company. It focuses its investments on start-ups with breakthrough technologies, applicable in emerging therapeutic segments. The company was founded in 1997 and is headquartered in Tel-Aviv, Israel.

Anchiano Therapeutics Ltd. is a clinical-stage biopharmaceutical company, which engages in tin the discovery, development and commercialization of drugs for cancer-related diseases. Its products include two drugs for cancer BC-819 and BC-821. The company was founded by Avraham Hochberg in 2004 and is headquartered in Jerusalem, Israel.

BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel.

Campus Bio Management Ltd. engages in the development of biopharmaceuticals and medical devices licensed from academic institutes for cancer and inflammatory diseases. The company was founded in May 2008 and is headquartered in Tel Aviv, Israel.

Part of Clal Biotechnology Industries Ltd., ARTE Venture Group Ltd. is an alternative investment manager. The private company is based in Ramat Gan, Israel. ARTE Venture Group was founded in 2003.

Part of Gamida Cell Ltd., Gamida Cell, Inc. develops cellular and immune therapeutics. The private company is based in Medfield, MA. The CEO of the company is Julian Adams.

Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA.

Anatomy Medical Technology Fund invests in companies located in Israel. The fund targets companies operating in the fields of medical technology. It provides financing for seed and early stage capital requirements.

eXIthera Pharmaceuticals, Inc. develops and manufactures stroke prevention and antithrombosis drugs. Its drugs are based on the pathophysiological role of Factor XI in the initiation of intravascular thrombi without causing undue bleeding. The firm’s drug candidates are small, orally active, and highly selective Factor XI inhibitors. The company was founded by Neil J. Hayward and Frans L. Stassen in 2012 and is headquartered in Westborough, MA.